HER2-Targeted Nanoliposome Therapy Activates Immune Response by Converting Cold to Hot Breast Tumors
Introduction HER2-positive breast cancer, accounting for 15%-20% of cases, remains challenging due to therapy resistance and immunosuppressive “cold tumor” microenvironments. Current strategies combining immunotherapy with chemotherapy or radiotherapy often face toxicity limitations. To address this...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-07-01
|
| Series: | Technology in Cancer Research & Treatment |
| Online Access: | https://doi.org/10.1177/15330338251356387 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|